Bristol-Myers Squibb: all 2,184 studies

Page 13 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Study to Determine the Pharmacokinetic Profile of BMS-986165 TabletsCompletedNCT04065932Phase 1
• A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy ParticipantsCompletedNCT04055506Phase 1
• A Study of Nivolumab in Patients With Head and Neck Cancer.CompletedNCT04050761
• CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and GlioblastomaTerminatedNCT04047303Phase 1
• A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.CompletedNCT04045639
• A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in JapanCompletedNCT04043975
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3
• Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate MofetilCompletedNCT04039373Phase 1
• A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT04036461Phase 1
• A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedNCT04036435Phase 3
• A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female ParticipantsCompletedNCT04016753Phase 1
• An Ascending Dose Study of BMS-986259 to Study Safety in Healthy ParticipantsCompletedNCT04008992Phase 1
• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
• A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingNCT03989414Phase 1/2
• Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT03983239Phase 1
• A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT03983161Phase 1
• A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsCompletedNCT03981094Phase 1
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1
• A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCompletedNCT03979248Phase 1
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With PsoriasisTerminatedNCT03971825Phase 1
• A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy SubjectsCompletedNCT03958864Phase 1
• Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese SubjectsCompletedNCT03956953Phase 1
• An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCompletedNCT03956680Phase 1
• A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy ParticipantsCompletedNCT03950960Phase 1
• Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male ParticipantsCompletedNCT03939702Phase 1
• A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy ParticipantsCompletedNCT03936374Phase 1
• A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingNCT03930953Phase 1/2
• Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165CompletedNCT03930602Phase 1
• To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT03915769Phase 3
• A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedNCT03906526Phase 1
• A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy ParticipantsCompletedNCT03891108Phase 1
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCompletedNCT03890809Phase 1
• A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.CompletedNCT03890770Phase 1
• Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCompletedNCT03873415Phase 1
• A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3
• A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
• A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients MalignanciesCompletedNCT03834662Phase 1
• Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic SclerosisCompletedNCT03831438Phase 1
• Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03824678Phase 1
• A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With NivolumabCompletedNCT03804554
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy SubjectsCompletedNCT03803644Phase 1
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2
• A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersTerminatedNCT03783403Phase 1
• A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedCompletedNCT03771859
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That OccurCompletedNCT03769558
• Evaluation of Safety and Effectiveness on Oral AnticoagulantsCompletedNCT03765242
• A Taste Assessment of BMS-986165 in Healthy ParticipantsCompletedNCT03751228Phase 1
• An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsCompletedNCT03745807Phase 1
• ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT03742921
• A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03742882Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCompletedNCT03739788Phase 1
• A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USCompletedNCT03732560
• Expanded Access for ACE-011No longer availableNCT03724227
• A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMCompletedNCT03723655Phase 2/3
• Expanded Access for CC-486Approved for marketingNCT03723135
• Expanded Access for CC-4047No longer availableNCT03723096
• Expanded Access for CC-2001No longer availableNCT03723083
• Expanded Access for AG-221No longer availableNCT03723057
• A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsCompletedNCT03720366Phase 1
• An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy ParticipantsCompletedNCT03712540Phase 1
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2
• A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsCompletedNCT03698513Phase 1
• Safety Study of Abatacept in Rheumatoid Arthritis ParticipantsCompletedNCT03696173
• A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced MelanomaCompletedNCT03696069
• Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor ResponseCompletedNCT03694119Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCompletedNCT03674476Phase 1
• A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic AgentsCompletedNCT03670667
• Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active MetabolitesCompletedNCT03665610
• A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has SpreadCompletedNCT03663946
• Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in AustraliaCompletedNCT03663829
• An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03661632Phase 1
• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerCompletedNCT03661320Phase 3
• An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsCompletedNCT03660436Phase 1
• Postmarketing Study of Empliciti in Korean Patients With Multiple MyelomaWithdrawnNCT03660072
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT03647124
• Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart RateCompletedNCT03644576Phase 1
• Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System CellsCompletedNCT03644498
• An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy ParticipantsCompletedNCT03634995Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired ParticipantsCompletedNCT03634969Phase 1
• Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3ACompletedNCT03624959Phase 1
• A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in SpainCompletedNCT03602755
• An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedNCT03601078Phase 2
• The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the LungCompletedNCT03595891
• Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has SpreadCompletedNCT03569436
• Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer ParticipantsCompletedNCT03568435
• Study of the Sudden Heart Failure Participant Population in the USWithdrawnNCT03566264
• An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy ParticipantsCompletedNCT03563950Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult SubjectsCompletedNCT03554993Phase 1
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCompletedNCT03541564Phase 1
• A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood ClotCompletedNCT03521908
• A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac DiseaseCompletedNCT03521180
• An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCompletedNCT03515980Phase 1
• A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)Status unknownNCT03515655
• Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT03509896
• Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart FailureCompletedNCT03508271
• Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)WithdrawnNCT03508258

← Bristol-Myers Squibb overview and focus areas